SAFETYLIT WEEKLY UPDATE

We compile citations and summaries of about 400 new articles every week.
RSS Feed

HELP: Tutorials | FAQ
CONTACT US: Contact info

Search Results

Journal Article

Citation

Drake C, Gumenyuk V, Roth T, Howard R. Sleep 2014; 37(12): 1987-1994.

Affiliation

Sleep Disorders & Research Center, Henry Ford Health System, Detroit, MI.

Copyright

(Copyright © 2014, American Academy of Sleep Medicine, Publisher Associated Professional Sleep Societies)

DOI

unavailable

PMID

25325498

Abstract

STUDY OBJECTIVES: Forty-one percent of shift workers report dozing while driving. This study tested whether armodafinil improves driving simulator performance in subjects with shift work disorder (SWD). A primary outcome was performance late in the shift when workers are typically driving home.

DESIGN: Randomized, double-blind, crossover. During each 12-h test session (21:30-09:30), subjects were kept awake except for multiple sleep latency testing (MSLT: 01:30, 03:30, 05:30, and 07:30). Subjective sleepiness (Karolinska Sleepiness Scale, KSS), driving performance, and cognitive performance (digit symbol substitution test and creativity on the Remote Associates Test, RAT) were evaluated during the night shift and commute home times. SETTING: Hospital-based sleep research laboratory. PARTICIPANTS: Twenty night workers (age: 42.7 PARTICIPANTS: ± 8.7 y, 17 F) with excessive sleepiness (≥ 10 on the Epworth Sleepiness Scale), meeting International Classification of Sleep Disorders, Second Edition (ICSD-2) criteria for SWD, and having no other medical conditions. INTERVENTIONS: Armodafinil (150 mg) or placebo at (23:45 h) on counterbalanced nights separated by 7-14 days. MEASUREMENT AND RESULTS: Primary endpoints were driving simulator performance (standard deviation of lateral position (SDLP) and off-road deviations) with four sessions starting 3.25 h after drug administration, objective sleepiness (MSLT; 1.75 to 7.75 h post-drug), and creativity (5 h post-drug). Significant effects of drug were observed for each driving measure (P MEASUREMENT AND RESULTS: < MEASUREMENT AND RESULTS: 0.05). Armodafinil significantly improved SDLP for simulator sessions at 05:30, 07:30, and 09:30, and off-road deviations at 7 h, 15 min and 9 h, 15 min post-drug (P MEASUREMENT AND RESULTS: < MEASUREMENT AND RESULTS: 0.05). Armodafinil also improved objective sleepiness from 3.7 MEASUREMENT AND RESULTS: ± 0.6 min to 9.7 ± 5.2 min (P MEASUREMENT AND RESULTS: < MEASUREMENT AND RESULTS: 0.001) and RAT score from 8.75 MEASUREMENT AND RESULTS: ± 4.9 to 11.25 ± 6.0 (P MEASUREMENT AND RESULTS: < MEASUREMENT AND RESULTS: 0.005).

CONCLUSIONS: Armodafinil 150 mg early in the night shift improves driving simulator performance in SWD. Effects on sleepiness, cognition, and driving were found up to 9.5 h post-ingestion, during the critical time when many night workers are driving home.


Language: en

NEW SEARCH


All SafetyLit records are available for automatic download to Zotero & Mendeley
Print